nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP3A4—bone cancer	0.648	1	CbGaD
Trametinib—Phosphatase alkaline increased—Epirubicin—bone cancer	0.00054	0.00309	CcSEcCtD
Trametinib—Bradycardia—Cisplatin—bone cancer	0.000538	0.00308	CcSEcCtD
Trametinib—Hyperkalaemia—Epirubicin—bone cancer	0.000531	0.00304	CcSEcCtD
Trametinib—Melaena—Epirubicin—bone cancer	0.000528	0.00302	CcSEcCtD
Trametinib—Creatinine increased—Doxorubicin—bone cancer	0.000525	0.00301	CcSEcCtD
Trametinib—Mouth ulceration—Methotrexate—bone cancer	0.000522	0.00299	CcSEcCtD
Trametinib—Neoplasm—Methotrexate—bone cancer	0.000522	0.00299	CcSEcCtD
Trametinib—Urinary tract disorder—Cisplatin—bone cancer	0.000522	0.00299	CcSEcCtD
Trametinib—Connective tissue disorder—Cisplatin—bone cancer	0.000519	0.00297	CcSEcCtD
Trametinib—Urethral disorder—Cisplatin—bone cancer	0.000518	0.00296	CcSEcCtD
Trametinib—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.0005	0.00286	CcSEcCtD
Trametinib—Dry eye—Epirubicin—bone cancer	0.000499	0.00286	CcSEcCtD
Trametinib—Eye disorder—Cisplatin—bone cancer	0.000494	0.00283	CcSEcCtD
Trametinib—Hyperkalaemia—Doxorubicin—bone cancer	0.000491	0.00281	CcSEcCtD
Trametinib—Rash maculo-papular—Epirubicin—bone cancer	0.000491	0.00281	CcSEcCtD
Trametinib—Cardiac disorder—Cisplatin—bone cancer	0.00049	0.00281	CcSEcCtD
Trametinib—Mouth ulceration—Epirubicin—bone cancer	0.000488	0.0028	CcSEcCtD
Trametinib—Neoplasm—Epirubicin—bone cancer	0.000488	0.0028	CcSEcCtD
Trametinib—Melaena—Doxorubicin—bone cancer	0.000488	0.00279	CcSEcCtD
Trametinib—Mediastinal disorder—Cisplatin—bone cancer	0.000476	0.00272	CcSEcCtD
Trametinib—Arrhythmia—Cisplatin—bone cancer	0.000472	0.0027	CcSEcCtD
Trametinib—Dry eye—Doxorubicin—bone cancer	0.000462	0.00264	CcSEcCtD
Trametinib—Erythema—Cisplatin—bone cancer	0.00046	0.00263	CcSEcCtD
Trametinib—Malnutrition—Cisplatin—bone cancer	0.00046	0.00263	CcSEcCtD
Trametinib—Rash maculo-papular—Doxorubicin—bone cancer	0.000454	0.0026	CcSEcCtD
Trametinib—Renal failure acute—Methotrexate—bone cancer	0.000454	0.0026	CcSEcCtD
Trametinib—Mouth ulceration—Doxorubicin—bone cancer	0.000452	0.00259	CcSEcCtD
Trametinib—Neoplasm—Doxorubicin—bone cancer	0.000452	0.00259	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000451	0.00258	CcSEcCtD
Trametinib—Muscle spasms—Cisplatin—bone cancer	0.000442	0.00253	CcSEcCtD
Trametinib—Vision blurred—Cisplatin—bone cancer	0.000433	0.00248	CcSEcCtD
Trametinib—Cardiac failure congestive—Epirubicin—bone cancer	0.000432	0.00247	CcSEcCtD
Trametinib—Anaemia—Cisplatin—bone cancer	0.000425	0.00243	CcSEcCtD
Trametinib—Renal failure acute—Epirubicin—bone cancer	0.000425	0.00243	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000417	0.00239	CcSEcCtD
Trametinib—Leukopenia—Cisplatin—bone cancer	0.000412	0.00236	CcSEcCtD
Trametinib—Cardiac failure congestive—Doxorubicin—bone cancer	0.0004	0.00229	CcSEcCtD
Trametinib—Hyponatraemia—Epirubicin—bone cancer	0.000394	0.00225	CcSEcCtD
Trametinib—Renal failure acute—Doxorubicin—bone cancer	0.000393	0.00225	CcSEcCtD
Trametinib—Pain in extremity—Epirubicin—bone cancer	0.000392	0.00224	CcSEcCtD
Trametinib—Myalgia—Cisplatin—bone cancer	0.000391	0.00224	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000389	0.00223	CcSEcCtD
Trametinib—Oedema—Cisplatin—bone cancer	0.000375	0.00215	CcSEcCtD
Trametinib—Infection—Cisplatin—bone cancer	0.000373	0.00213	CcSEcCtD
Trametinib—Nervous system disorder—Cisplatin—bone cancer	0.000368	0.00211	CcSEcCtD
Trametinib—Thrombocytopenia—Cisplatin—bone cancer	0.000367	0.0021	CcSEcCtD
Trametinib—Blood creatinine increased—Epirubicin—bone cancer	0.000367	0.0021	CcSEcCtD
Trametinib—Dehydration—Epirubicin—bone cancer	0.000365	0.00209	CcSEcCtD
Trametinib—Skin disorder—Cisplatin—bone cancer	0.000364	0.00209	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—bone cancer	0.000364	0.00208	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—bone cancer	0.000363	0.00208	CcSEcCtD
Trametinib—Hyperhidrosis—Cisplatin—bone cancer	0.000363	0.00208	CcSEcCtD
Trametinib—Dry skin—Epirubicin—bone cancer	0.000359	0.00206	CcSEcCtD
Trametinib—Abdominal pain upper—Epirubicin—bone cancer	0.000358	0.00205	CcSEcCtD
Trametinib—Hypokalaemia—Epirubicin—bone cancer	0.000357	0.00204	CcSEcCtD
Trametinib—Pancreatitis—Methotrexate—bone cancer	0.000355	0.00203	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000353	0.00202	CcSEcCtD
Trametinib—Abdominal discomfort—Methotrexate—bone cancer	0.000347	0.00199	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000346	0.00198	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000342	0.00196	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—bone cancer	0.00034	0.00195	CcSEcCtD
Trametinib—Neutropenia—Methotrexate—bone cancer	0.000339	0.00194	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—bone cancer	0.000337	0.00193	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—bone cancer	0.000333	0.0019	CcSEcCtD
Trametinib—Pancreatitis—Epirubicin—bone cancer	0.000332	0.0019	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—bone cancer	0.000331	0.0019	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—bone cancer	0.00033	0.00189	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000327	0.00187	CcSEcCtD
Trametinib—Decreased appetite—Cisplatin—bone cancer	0.000326	0.00187	CcSEcCtD
Trametinib—Gastrointestinal disorder—Cisplatin—bone cancer	0.000324	0.00185	CcSEcCtD
Trametinib—Infestation NOS—Methotrexate—bone cancer	0.000323	0.00185	CcSEcCtD
Trametinib—Infestation—Methotrexate—bone cancer	0.000323	0.00185	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00032	0.00183	CcSEcCtD
Trametinib—Renal failure—Methotrexate—bone cancer	0.000317	0.00182	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—bone cancer	0.000317	0.00181	CcSEcCtD
Trametinib—Stomatitis—Methotrexate—bone cancer	0.000315	0.0018	CcSEcCtD
Trametinib—Haematuria—Methotrexate—bone cancer	0.000308	0.00176	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—bone cancer	0.000307	0.00176	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—bone cancer	0.000306	0.00175	CcSEcCtD
Trametinib—Epistaxis—Methotrexate—bone cancer	0.000305	0.00174	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—bone cancer	0.000302	0.00173	CcSEcCtD
Trametinib—Infestation—Epirubicin—bone cancer	0.000302	0.00173	CcSEcCtD
Trametinib—Renal failure—Epirubicin—bone cancer	0.000297	0.0017	CcSEcCtD
Trametinib—Body temperature increased—Cisplatin—bone cancer	0.000297	0.0017	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—bone cancer	0.000295	0.00169	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—bone cancer	0.000294	0.00168	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—bone cancer	0.000293	0.00168	CcSEcCtD
Trametinib—Haemoglobin—Methotrexate—bone cancer	0.000291	0.00167	CcSEcCtD
Trametinib—Haemorrhage—Methotrexate—bone cancer	0.00029	0.00166	CcSEcCtD
Trametinib—Haematuria—Epirubicin—bone cancer	0.000288	0.00165	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—bone cancer	0.000286	0.00164	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—bone cancer	0.000285	0.00163	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—bone cancer	0.000284	0.00163	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—bone cancer	0.000283	0.00162	CcSEcCtD
Trametinib—Infestation—Doxorubicin—bone cancer	0.00028	0.0016	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—bone cancer	0.00028	0.0016	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—bone cancer	0.000276	0.00158	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—bone cancer	0.000275	0.00157	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—bone cancer	0.000273	0.00156	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—bone cancer	0.000273	0.00156	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—bone cancer	0.000272	0.00156	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—bone cancer	0.000271	0.00155	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—bone cancer	0.000271	0.00155	CcSEcCtD
Trametinib—Asthenia—Cisplatin—bone cancer	0.000269	0.00154	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—bone cancer	0.000269	0.00154	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—bone cancer	0.000268	0.00153	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—bone cancer	0.000267	0.00153	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—bone cancer	0.000267	0.00153	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—bone cancer	0.000267	0.00153	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—bone cancer	0.000266	0.00152	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—bone cancer	0.000264	0.00151	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—bone cancer	0.000263	0.00151	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—bone cancer	0.000261	0.0015	CcSEcCtD
Trametinib—Chills—Methotrexate—bone cancer	0.00026	0.00149	CcSEcCtD
Trametinib—Diarrhoea—Cisplatin—bone cancer	0.000257	0.00147	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—bone cancer	0.000255	0.00146	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—bone cancer	0.000254	0.00145	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—bone cancer	0.000253	0.00145	CcSEcCtD
Trametinib—Erythema—Methotrexate—bone cancer	0.000252	0.00144	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—bone cancer	0.000252	0.00144	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—bone cancer	0.000252	0.00144	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—bone cancer	0.000252	0.00144	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—bone cancer	0.000251	0.00144	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—bone cancer	0.000248	0.00142	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—bone cancer	0.000247	0.00142	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—bone cancer	0.000247	0.00141	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—bone cancer	0.000247	0.00141	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—bone cancer	0.000246	0.00141	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—bone cancer	0.000246	0.00141	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—bone cancer	0.000244	0.0014	CcSEcCtD
Trametinib—Back pain—Methotrexate—bone cancer	0.000244	0.0014	CcSEcCtD
Trametinib—Chills—Epirubicin—bone cancer	0.000243	0.00139	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—bone cancer	0.000242	0.00139	CcSEcCtD
Trametinib—Vomiting—Cisplatin—bone cancer	0.000239	0.00137	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—bone cancer	0.000238	0.00136	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—bone cancer	0.000238	0.00136	CcSEcCtD
Trametinib—Rash—Cisplatin—bone cancer	0.000237	0.00135	CcSEcCtD
Trametinib—Dermatitis—Cisplatin—bone cancer	0.000236	0.00135	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—bone cancer	0.000236	0.00135	CcSEcCtD
Trametinib—Erythema—Epirubicin—bone cancer	0.000236	0.00135	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—bone cancer	0.000235	0.00134	CcSEcCtD
Trametinib—Anaemia—Methotrexate—bone cancer	0.000233	0.00133	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—bone cancer	0.000233	0.00133	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—bone cancer	0.000231	0.00132	CcSEcCtD
Trametinib—Back pain—Epirubicin—bone cancer	0.000228	0.00131	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—bone cancer	0.000228	0.0013	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—bone cancer	0.000227	0.0013	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—bone cancer	0.000226	0.00129	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—bone cancer	0.000226	0.00129	CcSEcCtD
Trametinib—Chills—Doxorubicin—bone cancer	0.000225	0.00129	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—bone cancer	0.000224	0.00128	CcSEcCtD
Trametinib—Nausea—Cisplatin—bone cancer	0.000223	0.00128	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—bone cancer	0.000223	0.00127	CcSEcCtD
Trametinib—Cough—Methotrexate—bone cancer	0.00022	0.00126	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—bone cancer	0.00022	0.00126	CcSEcCtD
Trametinib—Erythema—Doxorubicin—bone cancer	0.000218	0.00125	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—bone cancer	0.000218	0.00125	CcSEcCtD
Trametinib—Anaemia—Epirubicin—bone cancer	0.000218	0.00125	CcSEcCtD
Trametinib—Myalgia—Methotrexate—bone cancer	0.000215	0.00123	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—bone cancer	0.000215	0.00123	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—bone cancer	0.000214	0.00122	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000213	0.00122	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—bone cancer	0.000211	0.00121	CcSEcCtD
Trametinib—Back pain—Doxorubicin—bone cancer	0.000211	0.00121	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—bone cancer	0.00021	0.0012	CcSEcCtD
Trametinib—Cough—Epirubicin—bone cancer	0.000206	0.00118	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—bone cancer	0.000206	0.00118	CcSEcCtD
Trametinib—Infection—Methotrexate—bone cancer	0.000205	0.00117	CcSEcCtD
Trametinib—Hypertension—Epirubicin—bone cancer	0.000204	0.00117	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—bone cancer	0.000202	0.00116	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—bone cancer	0.000202	0.00116	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—bone cancer	0.000202	0.00115	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—bone cancer	0.000201	0.00115	CcSEcCtD
Trametinib—Myalgia—Epirubicin—bone cancer	0.000201	0.00115	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—bone cancer	0.0002	0.00114	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.0002	0.00114	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—bone cancer	0.000199	0.00114	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—bone cancer	0.000197	0.00113	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—bone cancer	0.000196	0.00112	CcSEcCtD
Trametinib—Oedema—Epirubicin—bone cancer	0.000193	0.0011	CcSEcCtD
Trametinib—Infection—Epirubicin—bone cancer	0.000191	0.0011	CcSEcCtD
Trametinib—MAP2K1—Signaling by EGFR—KIT—bone cancer	0.000191	0.00108	CbGpPWpGaD
Trametinib—Cough—Doxorubicin—bone cancer	0.000191	0.00109	CcSEcCtD
Trametinib—MAP2K2—Toll Like Receptor 4 (TLR4) Cascade—JUN—bone cancer	0.00019	0.00107	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—KIT—bone cancer	0.000189	0.00107	CbGpPWpGaD
Trametinib—MAP2K1—Activated TLR4 signalling—JUN—bone cancer	0.000189	0.00107	CbGpPWpGaD
Trametinib—Nervous system disorder—Epirubicin—bone cancer	0.000189	0.00108	CcSEcCtD
Trametinib—MAP2K1—MAPK Signaling Pathway—BRAF—bone cancer	0.000189	0.00107	CbGpPWpGaD
Trametinib—Thrombocytopenia—Epirubicin—bone cancer	0.000189	0.00108	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—bone cancer	0.000189	0.00108	CcSEcCtD
Trametinib—MAP2K1—Signaling by PDGF—KIT—bone cancer	0.000189	0.00106	CbGpPWpGaD
Trametinib—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000188	0.00107	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—bone cancer	0.000187	0.00107	CcSEcCtD
Trametinib—MAP2K2—PDGFR-beta signaling pathway—JUN—bone cancer	0.000186	0.00105	CbGpPWpGaD
Trametinib—Hyperhidrosis—Epirubicin—bone cancer	0.000186	0.00107	CcSEcCtD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—MDM2—bone cancer	0.000186	0.00105	CbGpPWpGaD
Trametinib—Insomnia—Methotrexate—bone cancer	0.000186	0.00107	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—bone cancer	0.000186	0.00106	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—bone cancer	0.000186	0.00106	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000185	0.00106	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB4—MDM2—bone cancer	0.000183	0.00103	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—BRAF—bone cancer	0.000183	0.00103	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.000183	0.00103	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—MDM2—bone cancer	0.000182	0.00103	CbGpPWpGaD
Trametinib—Dry mouth—Doxorubicin—bone cancer	0.000182	0.00104	CcSEcCtD
Trametinib—MAP2K1—Signaling by FGFR in disease—BRAF—bone cancer	0.000181	0.00102	CbGpPWpGaD
Trametinib—MAP2K2—L1CAM interactions—EGFR—bone cancer	0.000181	0.00102	CbGpPWpGaD
Trametinib—Decreased appetite—Methotrexate—bone cancer	0.000179	0.00102	CcSEcCtD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—JUN—bone cancer	0.000178	0.00101	CbGpPWpGaD
Trametinib—Oedema—Doxorubicin—bone cancer	0.000178	0.00102	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—bone cancer	0.000178	0.00102	CcSEcCtD
Trametinib—MAP2K1—Toll Like Receptor 4 (TLR4) Cascade—JUN—bone cancer	0.000178	0.001	CbGpPWpGaD
Trametinib—Fatigue—Methotrexate—bone cancer	0.000178	0.00102	CcSEcCtD
Trametinib—Infection—Doxorubicin—bone cancer	0.000177	0.00101	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000176	0.001	CcSEcCtD
Trametinib—MAP2K2—Downstream signal transduction—MDM2—bone cancer	0.000175	0.000987	CbGpPWpGaD
Trametinib—Nervous system disorder—Doxorubicin—bone cancer	0.000175	0.001	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—bone cancer	0.000175	0.000999	CcSEcCtD
Trametinib—MAP2K1—PDGFR-beta signaling pathway—JUN—bone cancer	0.000174	0.000983	CbGpPWpGaD
Trametinib—Insomnia—Epirubicin—bone cancer	0.000174	0.000998	CcSEcCtD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—MDM2—bone cancer	0.000174	0.000983	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—MDM2—bone cancer	0.000174	0.000982	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—MDM2—bone cancer	0.000173	0.000978	CbGpPWpGaD
Trametinib—Skin disorder—Doxorubicin—bone cancer	0.000173	0.000991	CcSEcCtD
Trametinib—MAP2K2—Signaling by GPCR—GRM4—bone cancer	0.000173	0.000974	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—RGS1—bone cancer	0.000173	0.000974	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—MDM2—bone cancer	0.000173	0.000973	CbGpPWpGaD
Trametinib—Hyperhidrosis—Doxorubicin—bone cancer	0.000172	0.000987	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways in Glioblastoma—TP53—bone cancer	0.000172	0.000972	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.000172	0.000968	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—MDM2—bone cancer	0.000172	0.000967	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—BRAF—bone cancer	0.000171	0.000966	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	0.000171	0.000965	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.000171	0.000963	CbGpPWpGaD
Trametinib—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.00017	0.000959	CbGpPWpGaD
Trametinib—MAP2K1—L1CAM interactions—EGFR—bone cancer	0.000169	0.000955	CbGpPWpGaD
Trametinib—MAP2K2—Toll-Like Receptors Cascades—JUN—bone cancer	0.000169	0.000954	CbGpPWpGaD
Trametinib—MAP2K2—ErbB1 downstream signaling—EGFR—bone cancer	0.000168	0.00095	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Methotrexate—bone cancer	0.000168	0.000964	CcSEcCtD
Trametinib—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000168	0.000946	CbGpPWpGaD
Trametinib—Decreased appetite—Epirubicin—bone cancer	0.000168	0.000959	CcSEcCtD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—JUN—bone cancer	0.000167	0.000941	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—JUN—bone cancer	0.000166	0.000938	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Epirubicin—bone cancer	0.000166	0.000952	CcSEcCtD
Trametinib—Fatigue—Epirubicin—bone cancer	0.000166	0.000951	CcSEcCtD
Trametinib—Constipation—Epirubicin—bone cancer	0.000165	0.000943	CcSEcCtD
Trametinib—MAP2K2—Signaling by SCF-KIT—MMP9—bone cancer	0.000165	0.000928	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—MDM2—bone cancer	0.000164	0.000924	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—MDM2—bone cancer	0.000163	0.000919	CbGpPWpGaD
Trametinib—Abdominal pain—Methotrexate—bone cancer	0.000163	0.000932	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—bone cancer	0.000163	0.000932	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000162	0.00093	CcSEcCtD
Trametinib—MAP2K2—DAP12 interactions—MDM2—bone cancer	0.000162	0.000915	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	0.000162	0.000915	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—MDM2—bone cancer	0.000162	0.000915	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—MDM2—bone cancer	0.000162	0.000915	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—RGS1—bone cancer	0.000162	0.000911	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—GRM4—bone cancer	0.000162	0.000911	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—MDM2—bone cancer	0.000161	0.00091	CbGpPWpGaD
Trametinib—Insomnia—Doxorubicin—bone cancer	0.000161	0.000923	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways in Glioblastoma—TP53—bone cancer	0.000161	0.000909	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—MDM2—bone cancer	0.000161	0.000907	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.000161	0.000905	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	0.00016	0.000903	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—MDM2—bone cancer	0.000159	0.000899	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—MDM2—bone cancer	0.000159	0.000895	CbGpPWpGaD
Trametinib—MAP2K1—Toll-Like Receptors Cascades—JUN—bone cancer	0.000158	0.000893	CbGpPWpGaD
Trametinib—MAP2K1—ErbB1 downstream signaling—EGFR—bone cancer	0.000158	0.000889	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Epirubicin—bone cancer	0.000158	0.000902	CcSEcCtD
Trametinib—MAP2K1—BDNF signaling pathway—JUN—bone cancer	0.000156	0.000878	CbGpPWpGaD
Trametinib—Decreased appetite—Doxorubicin—bone cancer	0.000155	0.000887	CcSEcCtD
Trametinib—MAP2K1—Signaling by SCF-KIT—MMP9—bone cancer	0.000154	0.000869	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000154	0.000881	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—bone cancer	0.000154	0.00088	CcSEcCtD
Trametinib—MAP2K2—Insulin Signaling—JUN—bone cancer	0.000153	0.000863	CbGpPWpGaD
Trametinib—Constipation—Doxorubicin—bone cancer	0.000152	0.000873	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—bone cancer	0.000152	0.000872	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—bone cancer	0.000152	0.000872	CcSEcCtD
Trametinib—MAP2K1—DAP12 interactions—MDM2—bone cancer	0.000152	0.000856	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	0.000152	0.000856	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—MDM2—bone cancer	0.000152	0.000856	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—JUN—bone cancer	0.000151	0.000854	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—MDM2—bone cancer	0.00015	0.000849	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—GRM1—bone cancer	0.00015	0.000844	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—MDM2—bone cancer	0.000149	0.000841	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—MDM2—bone cancer	0.000149	0.000837	CbGpPWpGaD
Trametinib—Asthenia—Methotrexate—bone cancer	0.000148	0.000846	CcSEcCtD
Trametinib—MAP2K2—MAPK Signaling Pathway—JUN—bone cancer	0.000147	0.00083	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Doxorubicin—bone cancer	0.000146	0.000835	CcSEcCtD
Trametinib—Pruritus—Methotrexate—bone cancer	0.000146	0.000834	CcSEcCtD
Trametinib—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.000145	0.00082	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.000144	0.000811	CbGpPWpGaD
Trametinib—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.000143	0.000809	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—JUN—bone cancer	0.000143	0.000807	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000143	0.000806	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—JUN—bone cancer	0.000142	0.000799	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	0.000141	0.000796	CbGpPWpGaD
Trametinib—Abdominal pain—Doxorubicin—bone cancer	0.000141	0.000807	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—bone cancer	0.000141	0.000807	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—bone cancer	0.000141	0.000806	CcSEcCtD
Trametinib—MAP2K2—Innate Immune System—ATF1—bone cancer	0.000141	0.000793	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—KIT—bone cancer	0.00014	0.000792	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—GRM1—bone cancer	0.00014	0.00079	CbGpPWpGaD
Trametinib—Asthenia—Epirubicin—bone cancer	0.000138	0.000791	CcSEcCtD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000138	0.000777	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—JUN—bone cancer	0.000138	0.000776	CbGpPWpGaD
Trametinib—Pruritus—Epirubicin—bone cancer	0.000136	0.00078	CcSEcCtD
Trametinib—Dizziness—Methotrexate—bone cancer	0.000136	0.000779	CcSEcCtD
Trametinib—MAP2K2—Axon guidance—MET—bone cancer	0.000135	0.000761	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.000134	0.000758	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—JUN—bone cancer	0.000133	0.000752	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by SCF-KIT—EGFR—bone cancer	0.000133	0.00075	CbGpPWpGaD
Trametinib—MAP2K1—Senescence and Autophagy in Cancer—TP53—bone cancer	0.000132	0.000746	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	0.000132	0.000744	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—BRAF—bone cancer	0.000132	0.000744	CbGpPWpGaD
Trametinib—Diarrhoea—Epirubicin—bone cancer	0.000132	0.000755	CcSEcCtD
Trametinib—MAP2K1—Innate Immune System—ATF1—bone cancer	0.000132	0.000742	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—KIT—bone cancer	0.000131	0.000741	CbGpPWpGaD
Trametinib—Vomiting—Methotrexate—bone cancer	0.000131	0.000749	CcSEcCtD
Trametinib—Rash—Methotrexate—bone cancer	0.00013	0.000743	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—bone cancer	0.00013	0.000742	CcSEcCtD
Trametinib—Headache—Methotrexate—bone cancer	0.000129	0.000738	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—bone cancer	0.000128	0.000732	CcSEcCtD
Trametinib—Dizziness—Epirubicin—bone cancer	0.000127	0.000729	CcSEcCtD
Trametinib—MAP2K2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000127	0.000718	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—EGFR—bone cancer	0.000127	0.000718	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MET—bone cancer	0.000126	0.000712	CbGpPWpGaD
Trametinib—Pruritus—Doxorubicin—bone cancer	0.000126	0.000722	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB4—EGFR—bone cancer	0.000125	0.000707	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—JUN—bone cancer	0.000125	0.000703	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—EGFR—bone cancer	0.000124	0.000702	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000124	0.0007	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—BRAF—bone cancer	0.000123	0.000696	CbGpPWpGaD
Trametinib—Vomiting—Epirubicin—bone cancer	0.000123	0.000701	CcSEcCtD
Trametinib—Nausea—Methotrexate—bone cancer	0.000122	0.0007	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—bone cancer	0.000122	0.000698	CcSEcCtD
Trametinib—Rash—Epirubicin—bone cancer	0.000121	0.000695	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—bone cancer	0.000121	0.000695	CcSEcCtD
Trametinib—Headache—Epirubicin—bone cancer	0.000121	0.000691	CcSEcCtD
Trametinib—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000121	0.00068	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—EGFR—bone cancer	0.00012	0.000675	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000119	0.000672	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—EGFR—bone cancer	0.000119	0.000672	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—EGFR—bone cancer	0.000119	0.000671	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—EGFR—bone cancer	0.000119	0.000671	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—EGFR—bone cancer	0.000118	0.000668	CbGpPWpGaD
Trametinib—Dizziness—Doxorubicin—bone cancer	0.000118	0.000675	CcSEcCtD
Trametinib—MAP2K2—DAP12 signaling—EGFR—bone cancer	0.000118	0.000665	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—TP53—bone cancer	0.000118	0.000664	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—EGFR—bone cancer	0.000117	0.000661	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—EGFR—bone cancer	0.000116	0.000652	CbGpPWpGaD
Trametinib—Nausea—Epirubicin—bone cancer	0.000114	0.000655	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—bone cancer	0.000113	0.000649	CcSEcCtD
Trametinib—MAP2K2—Axon guidance—MMP2—bone cancer	0.000113	0.000635	CbGpPWpGaD
Trametinib—Rash—Doxorubicin—bone cancer	0.000112	0.000643	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—bone cancer	0.000112	0.000643	CcSEcCtD
Trametinib—MAP2K1—Downstream signal transduction—EGFR—bone cancer	0.000112	0.000631	CbGpPWpGaD
Trametinib—Headache—Doxorubicin—bone cancer	0.000112	0.000639	CcSEcCtD
Trametinib—MAP2K1—Signaling by FGFR—EGFR—bone cancer	0.000111	0.000628	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—EGFR—bone cancer	0.000111	0.000628	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—EGFR—bone cancer	0.000111	0.000625	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	0.000111	0.000625	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—EGFR—bone cancer	0.000111	0.000625	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—EGFR—bone cancer	0.000111	0.000625	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—MDM2—bone cancer	0.000111	0.000624	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—EGFR—bone cancer	0.00011	0.000622	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—TP53—bone cancer	0.00011	0.000621	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—EGFR—bone cancer	0.00011	0.00062	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—EGFR—bone cancer	0.000109	0.000614	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—EGFR—bone cancer	0.000108	0.000612	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—EGFR—bone cancer	0.000108	0.00061	CbGpPWpGaD
Trametinib—Nausea—Doxorubicin—bone cancer	0.000106	0.000606	CcSEcCtD
Trametinib—MAP2K2—Signaling by GPCR—SMO—bone cancer	0.000105	0.000595	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MMP2—bone cancer	0.000105	0.000594	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—EGFR—bone cancer	0.000105	0.000591	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	0.000104	0.000585	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—EGFR—bone cancer	0.000104	0.000585	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—EGFR—bone cancer	0.000104	0.000585	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—MDM2—bone cancer	0.000103	0.000583	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—EGFR—bone cancer	0.000103	0.00058	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RGS1—bone cancer	0.000102	0.000575	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GRM4—bone cancer	0.000102	0.000575	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NDUFA12—bone cancer	0.000102	0.000575	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—EGFR—bone cancer	0.000102	0.000575	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—EGFR—bone cancer	0.000101	0.000572	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—SMO—bone cancer	9.87e-05	0.000557	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	9.82e-05	0.000554	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—EGFR—bone cancer	9.81e-05	0.000553	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	9.76e-05	0.000551	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—bone cancer	9.71e-05	0.000548	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—GNA11—bone cancer	9.65e-05	0.000544	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MET—bone cancer	9.63e-05	0.000543	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CDK4—bone cancer	9.63e-05	0.000543	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GRM4—bone cancer	9.54e-05	0.000538	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RGS1—bone cancer	9.54e-05	0.000538	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	9.49e-05	0.000535	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ENO2—bone cancer	9.39e-05	0.000529	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	9.19e-05	0.000518	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—bone cancer	9.08e-05	0.000512	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—GNA11—bone cancer	9.03e-05	0.000509	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CDK4—bone cancer	9.01e-05	0.000508	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MET—bone cancer	9.01e-05	0.000508	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	8.88e-05	0.000501	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GRM1—bone cancer	8.84e-05	0.000499	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ENO2—bone cancer	8.78e-05	0.000495	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL3—bone cancer	8.75e-05	0.000493	CbGpPWpGaD
Trametinib—MAP2K2—Disease—DHFR—bone cancer	8.71e-05	0.000491	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—MMP9—bone cancer	8.46e-05	0.000477	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NT5C3A—bone cancer	8.45e-05	0.000476	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GRM1—bone cancer	8.27e-05	0.000467	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8.2e-05	0.000462	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ATF1—bone cancer	8.19e-05	0.000462	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL3—bone cancer	8.18e-05	0.000461	CbGpPWpGaD
Trametinib—MAP2K1—Disease—DHFR—bone cancer	8.15e-05	0.000459	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP2—bone cancer	8.03e-05	0.000453	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KIT—bone cancer	8.01e-05	0.000452	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL3—bone cancer	7.99e-05	0.000451	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—MMP9—bone cancer	7.92e-05	0.000446	CbGpPWpGaD
Trametinib—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.81e-05	0.00044	CbGpPWpGaD
Trametinib—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.7e-05	0.000434	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ATF1—bone cancer	7.67e-05	0.000432	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—bone cancer	7.56e-05	0.000426	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP2—bone cancer	7.52e-05	0.000424	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KIT—bone cancer	7.49e-05	0.000422	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL3—bone cancer	7.48e-05	0.000422	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—bone cancer	7.07e-05	0.000399	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—bone cancer	6.84e-05	0.000386	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—bone cancer	6.4e-05	0.000361	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFBR2—bone cancer	6.31e-05	0.000356	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MDM2—bone cancer	6.31e-05	0.000356	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SMO—bone cancer	6.23e-05	0.000351	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP9—bone cancer	6.04e-05	0.000341	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFBR2—bone cancer	5.9e-05	0.000333	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MDM2—bone cancer	5.9e-05	0.000333	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SMO—bone cancer	5.83e-05	0.000329	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GNA11—bone cancer	5.7e-05	0.000321	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP9—bone cancer	5.65e-05	0.000319	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—JUN—bone cancer	5.48e-05	0.000309	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NDUFA12—bone cancer	5.47e-05	0.000309	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GNA11—bone cancer	5.33e-05	0.000301	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ATF1—bone cancer	5.3e-05	0.000299	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL3—bone cancer	5.17e-05	0.000291	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—JUN—bone cancer	5.13e-05	0.000289	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ATF1—bone cancer	4.96e-05	0.00028	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—bone cancer	4.88e-05	0.000275	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL3—bone cancer	4.83e-05	0.000273	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KIT—bone cancer	4.66e-05	0.000263	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—bone cancer	4.57e-05	0.000257	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NT5C3A—bone cancer	4.54e-05	0.000256	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFBR2—bone cancer	4.42e-05	0.000249	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KIT—bone cancer	4.36e-05	0.000246	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—bone cancer	4.31e-05	0.000243	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KIT—bone cancer	4.31e-05	0.000243	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1R—bone cancer	4.16e-05	0.000234	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFBR2—bone cancer	4.13e-05	0.000233	CbGpPWpGaD
Trametinib—MAP2K2—Disease—BRAF—bone cancer	4.05e-05	0.000228	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—bone cancer	4.03e-05	0.000227	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KIT—bone cancer	4.03e-05	0.000227	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1R—bone cancer	3.89e-05	0.000219	CbGpPWpGaD
Trametinib—MAP2K1—Disease—BRAF—bone cancer	3.79e-05	0.000214	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ENO2—bone cancer	3.7e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MDM2—bone cancer	3.67e-05	0.000207	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MDM2—bone cancer	3.44e-05	0.000194	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—DHFR—bone cancer	3.43e-05	0.000194	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MDM2—bone cancer	3.39e-05	0.000191	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—bone cancer	3.27e-05	0.000184	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GNA11—bone cancer	3.21e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—JUN—bone cancer	3.19e-05	0.00018	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MDM2—bone cancer	3.17e-05	0.000179	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—bone cancer	3.06e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIT—bone cancer	3.02e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—JUN—bone cancer	2.99e-05	0.000168	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP3A4—bone cancer	2.91e-05	0.000164	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.89e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—bone cancer	2.83e-05	0.00016	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KIT—bone cancer	2.82e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—bone cancer	2.75e-05	0.000155	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—bone cancer	2.65e-05	0.00015	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—bone cancer	2.57e-05	0.000145	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—bone cancer	2.51e-05	0.000142	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—bone cancer	2.49e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MDM2—bone cancer	2.37e-05	0.000134	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—bone cancer	2.35e-05	0.000132	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—bone cancer	2.32e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MDM2—bone cancer	2.22e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—bone cancer	2.17e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JUN—bone cancer	2.06e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—bone cancer	2.01e-05	0.000113	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO2—bone cancer	1.99e-05	0.000112	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JUN—bone cancer	1.93e-05	0.000109	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—bone cancer	1.88e-05	0.000106	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—DHFR—bone cancer	1.84e-05	0.000104	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNA11—bone cancer	1.72e-05	9.71e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—bone cancer	1.62e-05	9.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—bone cancer	1.52e-05	8.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—bone cancer	1.36e-05	7.68e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—bone cancer	1.34e-05	7.53e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—bone cancer	1.29e-05	7.27e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—bone cancer	1.27e-05	7.19e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—bone cancer	6.92e-06	3.9e-05	CbGpPWpGaD
